EcoDrugPlus

D(1)-Like Dopamine Receptor

Ensembl ID : ENSMMDG00005012470
Gene Symbol: LOC115371945
3 Cross references
199 Possible Orthologues:

D(4) Dopamine Receptor-Like

Ensembl ID : ENSMMDG00005012704
Gene Symbol: LOC115356761
3 Cross references
181 Possible Orthologues:

D(4) Dopamine Receptor-Like

Ensembl ID : ENSMMDG00005017487
Gene Symbol: LOC115360287
3 Cross references
165 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSMMDG00005000480
Gene Symbol: DNMT1
3 Cross references
210 Possible Orthologues:

Dna Topoisomerase 1-Like

Ensembl ID : ENSMMDG00005007045
Gene Symbol: LOC115359385
3 Cross references
207 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSMMDG00005018372
Gene Symbol: TOP1
1 Cross references
198 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSMMDG00005015774
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSMMDG00005008636
Gene Symbol: TOP2B
1 Cross references
207 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSMMDG00005008132
Gene Symbol: EML4
1 Cross references
207 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSMMDG00005020057
Gene Symbol: EPHA3
3 Cross references
212 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSMMDG00005016394
Gene Symbol: F2RL3
1 Cross references
195 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSMMDG00005019597
Gene Symbol: FAU
3 Cross references
301 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).